Publicaciones científicas
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
Cristina Nanni 1 , Carsten Kobe 2 , Bettina Baeßler 3 , Christian Baues 4 , Ronald Boellaard 5 , Peter Borchmann 6 , Andreas Buck 7 , Irène Buvat 8 , Björn Chapuy 9 , Bruce D Cheson 10 , Robert Chrzan 11 , Ann-Segolene Cottereau 12 , Ulrich Dührsen 13 , Live Eikenes 14 , Martin Hutchings 15 , Wojciech Jurczak 16 , Françoise Kraeber-Bodéré 17 , Egesta Lopci 18 , Stefano Luminari 19 , Steven MacLennan 20 , N George Mikhaeel 21 , Marcel Nijland 22 , Paula Rodríguez-Otero 23 , Giorgio Treglia 24 , Nadia Withofs 25 , Elena Zamagni 26 , Pier Luigi Zinzani 26 , Josée M Zijlstra 27 , Ken Herrmann 28 , Jolanta Kunikowska 29
Abstract
Given the paucity of high-certainty evidence, and differences in opinion on the use of nuclear medicine for hematological malignancies, we embarked on a consensus process involving key experts in this area.
We aimed to assess consensus within a panel of experts on issues related to patient eligibility, imaging techniques, staging and response assessment, follow-up, and treatment decision-making, and to provide interim guidance by our expert consensus.
We used a three-stage consensus process. First, we systematically reviewed and appraised the quality of existing evidence. Second, we generated a list of 153 statements based on the literature review to be agreed or disagreed with, with an additional statement added after the first round.
Third, the 154 statements were scored by a panel of 26 experts purposively sampled from authors of published research on haematological tumours on a 1 (strongly disagree) to 9 (strongly agree) Likert scale in a two-round electronic Delphi review. The RAND and University of California Los Angeles appropriateness method was used for analysis. Between one and 14 systematic reviews were identified on each topic. All were rated as low to moderate quality. After two rounds of voting, there was consensus on 139 (90%) of 154 of the statements. There was consensus on most statements concerning the use of PET in non-Hodgkin and Hodgkin lymphoma. In multiple myeloma, more studies are required to define the optimal sequence for treatment assessment.
Furthermore, nuclear medicine physicians and haematologists are awaiting consistent literature to introduce volumetric parameters, artificial intelligence, machine learning, and radiomics into routine practice.
CITA DEL ARTÍCULO Lancet Haematol. 2023 May;10(5):e367-e381. doi: 10.1016/S2352-3026(23)00030-3
Nuestros autores
